RetiSpec Inc., a Toronto, Canada-based innovator in AI-driven eye diagnostics for brain health, closed a $10M USD Series A financing.
The round was led by iGan Partners and included new strategic investors, Eli Lilly and Company and Topcon Healthcare, Inc., along with existing investors, Gentex Corporation, the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator, Verge HealthTech Fund, University of Minnesota’s Discovery Capital, Ontario Brain Institute, Centre for Aging + Brain Health Innovation, and private investors. This financing brought RetiSpec’s total fundraising to $17M USD.
The company intends to use the funds to accelerate the commercialization of its technology aimed at early detection of Alzheimer’s disease.
Led by Eliav Shaked, Co-founder and CEO, RetiSpec is a medical AI company that aims to enable widespread early and accurate detection of neurodegenerative disease markers through an eye exam. Its AI solutions applied to non-invasive retinal images, provide real-time results at the point of care. RetiSpec’s first clinically validated AI is intended to predict amyloid burden to aid in the evaluation of individuals for Alzheimer’s disease. RetiSpec’s AI solutions are currently available for Research Use Only.
FinSMEs
29/07/2024